

Abe J, Umetsu R, Uranishi H, Suzuki H, Nishibata Y, Kato Y, Ueda N, Sasaoka S, Hatahira H, Motooka Y, Masuta M, Nakamura M. Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database. *PLoS One*. 2017 Dec 21.

Abeyaratne C, Lalic S, Bell JS, Ilomäki J. Spontaneously reported adverse drug events related to tapentadol and oxycodone/naloxone in Australia. *Ther Adv Drug Saf*. 2018 Apr; 9(4):197-205.

Ali AK, Watson DE. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies. *Pharmacotherapy*. 2017 Sep 26.

Ampadu HH, Hoekman J, de Bruin ML, Pal SN, Olsson S, Sartori D, Leufkens HG, Dodoo AN. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®. *Drug Saf*. 2016 Jan 11.

Ancuceanu R, Dinu M, Furtunescu F, Boda D. An inventory of medicinal products causing skin rash: Clinical and regulatory lessons. *Exp Ther Med*. 2019 Dec;18(6):5061-5071. doi: 10.3892/etm.2019.7837. Epub 2019 Jul 31.

Anderson LS, Bell HG, Gilbert M, Davidson JE, Winter C, Barratt MJ, Win B, Painter JL, Menone C, Sayegh J, Dasgupta N. Using Social Listening Data to Monitor Misuse and Nonmedical Use of Bupropion: A Content Analysis. *JMIR Public Health Surveill*. 2017 Feb 1; 3(1):e6.

Ankrah DNA, Darko DM, Sabblah G, Mantel-Teeuwisse A, Leufkens, HMG. Reporting of adverse events following immunizations in Ghana - Using disproportionality analysis reporting ratios. *Hum Vaccin Immunother*. 2017 Nov 27:1-7.

Anquetil C, Salem JE, Lebrun-Vignes B, et al. Evolving spectrum of drug-induced uveitis at the era of immune checkpoint inhibitors results from the WHO's pharmacovigilance database. *J Autoimmun*. 2020;111:102454. doi:10.1016/j.jaut.2020.102454

Arana JE, Harrington T, Cano M, Lewis P, Mba-Jonas A, Rongxia L, Stewart B, Markowitz LE, Shimabukuro TT. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015. *Vaccine*. 2018 Feb 21.

Aziz Y, Rademacher WMH, Hielema A, Wishaw SBP, van Diermen DE, de Lange J, Vissink A, Rozema FR. Oral adverse effects: drug-induced tongue disorders. *Oral Dis*. 2020 Oct 14. doi: 10.1111/odi.13680. Epub ahead of print. PMID: 33052611.

Bahk CY, Goshgarian M, Donahue K, Freifeld CC, Menone CM, Pierce CE, Rodriguez H, Brownstein JS, Furberg R, Dasgupta N. Increasing Patient Engagement in Pharmacovigilance Through Online Community Outreach and Mobile Reporting Applications: An Analysis of Adverse Event Reporting for the Essure Device in the US. *Pharmaceut Med.* 2015;29(6):331-340.

Basilua JM, Pochart P. Cotrimoxazole Prophylaxis Is Not Associated with a Higher occurrence of Atazanavir Treatment Failure: analysis of Worldwide Pharmacovigilance Data. *Infect Disord Drug Targets.* 2019 Dec 19. doi: 10.2174/1871526520666191220112416. [Epub ahead of print] PMID: 31858913

Bayer S, Clark C, Dang O, Aberdeen J, Brajovic S, Swank K, Hirschman L, Ball R. ADE Eval: An Evaluation of Text Processing Systems for Adverse Event Extraction from Drug Labels for Pharmacovigilance. *Drug Saf.* 2020 Oct 2. doi: 10.1007/s40264-020-00996-3. Epub ahead of print. PMID: 33006728.

Berg R, Shebl A, Kimber MC, Abraham M, Schreiber GB. Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012. *Transfusion.* 2015 Jul;55 Suppl 2:S36-46.

Biagi C, Conti V, Montanaro N, Melis M, Buccellato E, Donati M, Covezzoli A, Amato R, Pazzi L, Venegoni M, Vaccheri A, Motola D. Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions. *Eur J Clin Pharmacol.* 2014 Sep 20.

Blake KV, Zaccaria C, Domergue F, La Mache E, Saint-Raymond A, Hidalgo-Simon A. Comparison Between Paediatric and Adult Suspected Adverse Drug Reactions Reported to the European Medicines Agency: Implications for Pharmacovigilance. *Paediatr Drugs.* 2014 Jun 5.

Bonaldo G, Vaccheri A, Melis M, Motola D. Drug-induced disseminated intravascular coagulation: a pharmacovigilance study on World Health Organization's database [published online ahead of print, 2020 May 22]. *J Thromb Thrombolysis.* 2020;10.1007/s11239-020-02147-y. doi:10.1007/s11239-020-02147-y

Bondon-Guitton E, Combret S, Pérault-Pochat MC, Stève-Dumont M, Bagheri H, Huguet F, Despas F, Pathak A, Montastruc JL. Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy. *Target Oncol.* 2016 Feb 19.

Bossard JB, Ponté C, Dupouy J, Lapeyre-Mestre M, Jouanjus E. Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database. *Clin Drug Investig.* 2016 Jun 14.

Brajovic S, Blaser DA, Zisk M, Caligtan C, Okun S, Hall M, Pamer CA. Validating a Framework for Coding Patient-Reported Health Information to the Medical Dictionary for Regulatory Activities Terminology: An Evaluative Study. *JMIR Med Inform.* 2018 Aug 21;6(3):e42. doi: 10.2196/medinform.9878.

Calderón MA, Rodríguez Del Río P, Vidal C, Just J, Pfaar O, Linneberg A, Demoly P. An EAACI "European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI)": the methodology. *Clin Transl Allergy.* 2014 Jul 21;4:22.

Calderón MA, Vidal C, Rodríguez Del Río P, Just J, Pfaar O, Tabar AI, Sánchez-Machín I, Bubel P, Borja J, Eberle P, Reiber R, Bouvier M, Lepelliez A, Klimek L, Demoly P; EASSI Doctors' Group. European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a Real-Life Clinical Assessment. *Allergy.* 2016 Oct 8.

Card T, Ungaro R, Bhayat F, Blake A, Hantsbarger G, Travis S. Vedolizumab use is not associated with increased malignancy incidence: GEMINI LTS study results and post-marketing data. *Aliment Pharmacol Ther.* 2020 Jan;51(1):149-157. doi: 10.1111/apt.15538. Epub 2019 Nov 20. PMID: 31747086

Castillon G, Salvo F, Moride Y. The Social Impact of Suspected Adverse Drug Reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database. *Drug Saf.* 2018 Aug 19. doi: 10.1007/s40264-018-0713-8.

Chen C, Borrego ME, Roberts MH, Raisch DW. Comparison of post-marketing surveillance approaches regarding infections related to tumor necrosis factor inhibitors (TNFi's) used in treatment of autoimmune diseases. *Expert Opin Drug Saf.* 2019 Jun 20:1-12. doi: 10.1080/14740338.2019.1630063.

Chengwen T, Baus C, Wilson JP, Frei CR. Rhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS). *Int J Med Sci.* 2019 Oct 15. doi: 10.7150/ijms.38605.

Cho SB, Lee AL, Chang HW, Kim KA, Yoo WJ, Yeom JA, Rho MH, Kim SJ, Lim YJ, Han M. Prospective Multicenter Study of the Safety of Gadoteridol in 6163 Patients. *J Magn Reson Imaging.* 2019 Oct 29. doi: 10.1002/jmri.26940.

Chrétien B, Dolladille C, Hamel-Sénécal L, Sassier M, Faillie JL, Miremont-Salamé G, Lelong-Boulouard V, Le Boisselier R, Fedrizzi S, Alexandre J, Humbert X. Comparative study of hypoglycaemia induced by opioids. Is it a class effect? *Expert Opin Drug Saf.* 2019 Jul 24:1-6. doi: 10.1080/14740338.2019.1646246.

Chung AE, Shoenbill K, Mitchell SA, Dueck AC, Schrag D, Bruner DW, Minasian LM, St Germain D, O'Mara AM, Baumgartner P, Rogak LJ, Abernethy AP, Griffin AC, Basch EM. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). *J Am Med Inform Assoc.* 2019 Apr 1;26(4):276-285. doi: 10.1093/jamia/ocy169.

Cloitre A, Duval X, Tubiana S, Giraud P, Veyrac G, Nosbaum A, Gouraud A, Mahé J, Lesclous P. Antibiotic prophylaxis for the prevention of infective endocarditis for dental procedures is not associated with fatal adverse drug reactions in France. *Med Oral Patol Oral Cir Bucal.* 2019 Apr 23. pii: 22818. doi: 10.4317/medoral.22818.

Conte C, Rousseau V, Vert C, et al. Adverse drug reactions of statins in children and adolescents: a descriptive analysis from Vigibase, the WHO global database of individual case safety reports [published online ahead of print, 2020 Feb 5]. *Fundam Clin Pharmacol.* 2020;10.1111/fcp.12542. doi:10.1111/fcp.12542

Crescioli G, Lombardi N, Bettioli A, Menniti-Ippolito F, Da Cas R, Parrilli M, Del Lungo M, Gallo E, Mugelli A, Maggini V, Firenzuoli F, Vannacci A. Adverse events following Cannabis for medical use in Tuscany: an analysis of the Italian Phytovigilance database. *Br J Clin Pharmacol.* 2019 Oct 27. doi: 10.1111/bcp.14140.

Cutroneo PM, Giardina C, Ientile V, Potenza S, Sottosanti L, Ferrajolo C, Trombetta CJ, Trifirò G. Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System. *Drug Saf.* 2017 Jun 5.

Dagenais S, Scranton R, Joyce AR, Vick CC. A comparison of approaches to identify possible cases of local anesthetic systemic toxicity in the FDA Adverse Event Reporting System (FAERS) database. *Expert Opin Drug Saf.* 2018 May 10:1-8.

de Vries ST, Harrison J, Revella P, Ptaszynska-Neophytou A, Radecka A, Ragunathan G, Tregunno P, Denig P, Mol PGM. Use of a Patient-Friendly Terms List in the Adverse Drug Reaction Report Form:

A Database Study. *Drug Saf.* 2019 Feb 6. doi: 10.1007/s40264-019-00800-x.

Dietrich J, Gattepaille LM, Grum BA, et al. Adverse Events in Twitter-Development of a Benchmark Reference Dataset: Results from IMI WEB-RADR [published online ahead of print, 2020 Jan 29]. *Drug Saf.* 2020;10.1007/s40264-020-00912-9. doi:10.1007/s40264-020-00912-9

Du J, Cai Y, Chen Y, He Y, Tao C. Analysis of Individual Differences in Vaccine Pharmacovigilance Using VAERS Data and MedDRA System Organ Classes: A Use Case Study With Trivalent Influenza Vaccine. *Biomed Inform Insights.* 2017 Apr 11.

Dubrall D, Schmid M, Stingl JC, Sachs B. Angioedemas associated with renin-angiotensin system blocking drugs: Comparative analysis of spontaneous adverse drug reaction reports. *PLoS One.* 2020 Mar 26;15(3):e0230632. doi: 10.1371/journal.pone.0230632. eCollection 2020. PubMed PMID: 32214375; PubMed Central PMCID: PMC7098604.

Durup D(1), Schaffalitzky de Muckadell P(1), Strom CC(1). Evaluation of the reported rates of hypersensitivity reactions associated with iron dextran and ferric carboxymaltose based on global data from VigiBase™ and IQVIA™ MIDAS® over a ten-year period from 2008 to 2017. *Expert Rev Hematol.* 2020 Mar 4. doi: 10.1080/17474086.2020.1738215. [Epub ahead of print] DOI: 10.1080/17474086.2020.1738215

Ehlken B, Nathell L, Gohlke A, Bocuk D, Toussi M, Wohlfeil S. Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017. *Drug Saf.* 2018 Dec 10. doi: 10.1007/s40264-018-0769-5.

Emery P, Furst DE, Kirchner P, Melega S, Lacey S, Lehane PB. Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data. *Rheumatol Ther.* 2019 Nov 21. doi: 10.1007/s40744-019-00183-6.

Eriksson R, Aagaard L, Jensen LJ, Borisova L, Hørlück D, Brunak S, Hansen EH. Discrepancies in listed adverse drug reactions in pharmaceutical product information supplied by the regulatory authorities in Denmark and the USA. *Pharmacol Res Perspect.* 2014 Jun;2(3).

Fahmy AI, Mekkawy MA, Abou-Ali A. Evaluation of bleeding adverse events associated with oral P2Y12 inhibitors use in the Food and Drug Administration adverse event reporting system. *Int J Clin Pharmacol Ther.* 2019 Feb 10. doi: 10.5414/CP203365.

Faisant C, Armengol G, Bouillet L, Boccon-Gibod I, Villier C, Lévesque H, Cottin J, Massy N, Benhamou Y. Angioedema Triggered by Medication Blocking the Renin/Angiotensin System: Retrospective Study Using the French National Pharmacovigilance Database. *J Clin Immunol*. 2015 Dec 28.

Felicetti P, Trotta F, Bonetto C, Santuccio C, Pernus YB, Burgner D, Chandler R, Girolomoni G, Hadden RD, Kochar S, Kukucu M, Monaco G, Ozen S, Pahud B, Phuong L, Bachtiar NS, Teeba A, Top K, Varricchio F, Wise RP18, Zanoni G19, Živkovic S, Bonhoeffer J; Brighton Collaboration Vasculitis Working Group. Spontaneous reports of vasculitis as an adverse event following immunization: A descriptive analysis across three international databases. *Vaccine*. 2015 Sep 18. pii: S0264-410X(15)01293-1.

Freifeld CC, Brownstein JS, Menone CM, Bao W, Filice R, Kass-Hout T, Dasgupta N. Digital Drug Safety Surveillance: Monitoring Pharmaceutical Products in Twitter. *Drug Saf*. 2014 Apr 29.

Fukuda A, Tahara K, Hane Y, Matsui T, Sasaoka S, Hatahira H, Motooka Y, Hasegawa S, Naganuma M, Abe J, Nakao S, Takeuchi H, Nakamura M. Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system. *PLoS One*. 2017 Sep 27;12(9).

Gahr M, Zeiss R, Lang D, Connemann BJ, Hiemke C, Schönfeldt-Lecuona C. Drug-induced liver injury associated with antidepressive psychopharmacotherapy: An explorative assessment based on quantitative signal detection using different MedDRA terms. *J Clin Pharmacol*. 2015 Oct 16.

García MG, Larrinaga-Torrontegui U, Eduardo Martinez E, Lertxundi U, Palacios-Zabalza I, Aguirre C. Fractures Related to Tenofovir: A Case/Noncase Study in the European Pharmacovigilance Database. *Am J Ther*. 2018 Jan 8.

Gattás VL, Braga PE, Koike ME, Lucchesi MB, Precioso AR. Safety profile of heterologous serum produced by the Butantan Institute, in São Paulo-SP, Brazil, from 2012 to 2015. *Epidemiol Serv Saude*. 2017 Jul-Sep;26(3):639-647.

Giancane G, Swart JF, Castagnola E, Groll AH, Horneff G, Huppertz HI, Lovell DJ, Wolfs T, Herlin T, Dolezalova P, Sanner H, Susic G, Sztajn bok F, Maritsi D, Constantin T, Vargova V, Sawhney S, Rygg M, K Oliveira S, Cattalini M, Bovis F, Bagnasco F, Pistorio A, Martini A, Wulffraat N, Ruperto N; Paediatric Rheumatology International Trials Organisation (PRINTO). Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. *Arthritis Res Ther*. 2020 Apr 7;22(1):71. doi: 10.1186/s13075-020-02167-2.

PubMed PMID: 32264969; PubMed Central PMCID: PMC7136994.

Goedecke T, Ord K, Newbould V, Brosch S, Arlett P. Medication Errors: New EU Good Practice Guide on Risk Minimisation and Error Prevention. *Drug Saf.* 2016 Mar 3.

Gopal S, Hough D, Karcher K, Nuamah I, Palumbo J, Berlin JA, Baseman A, Xu Y, Kent J. Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials. *J Clin Psychopharmacol.* 2013 Apr;33(2):157-61.

Hasegawa S, Hatahira H, Naganuma M, Shimauchi A, Sasaoka S, Motooka Y, Fukuda A, Abe J, Nakao S, Kato Y, Ohmori T, Iguchi K, Nakamura M. Adverse Event Trends Associated with OTC Analgesic and Antipyretic Drug: Data Mining of the Japanese Adverse Drug Event Report Database. *Yakugaku Zasshi.* 2017;137(10):1301-1311.

Hasegawa S, Ikesue H, Nakao S, et al. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database [published online ahead of print, 2020 Sep 1]. *Pharmacoepidemiol Drug Saf.* 2020;10.1002/pds.5108. doi:10.1002/pds.5108

Hatahira H, Hasegawa S, Sasaoka S, Kato Y, Abe J, Motooka Y, Fukuda A, Naganuma M, Nakao S, Mukai R, Shimada K, Hirade K, Kato T, Nakamura M. Analysis of fall-related adverse events among older adults using the Japanese Adverse Drug Event Report (JADER) database. *J Pharm Health Care Sci.* 2018 Dec 17;4:32. doi: 10.1186/s40780-018-0129-8. eCollection 2018.

Hauben M, Hung E, Wood J, Soitkar A, Reshef D. The impact of database restriction on pharmacovigilance signal detection of selected cancer therapies. *Ther Adv Drug Saf.* 2017 May; 8(5): 145-156.

He Y, Sarntivijai S, Lin Y, Xiang Z, Guo A, Zhang S, Jagannathan D, Toldo L, Tao C, Smith, B. OAE: The Ontology of Adverse Events. *Journal of Biomedical Semantics* 2014, 5:29.

He Y, Toldo L, Burns G, Tao C, Abernethy DR. A 2012 Workshop: Vaccine and drug ontology in the study of mechanism and effect (VDOSME 2012). *J Biomed Semantics.* 2012 Dec 18;3(1):12.

Hoffman KB, Dimbil M, Kyle RF, Tatonetti NP, Erdman CB, Demakas A, Chen D, Overstreet BM. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes. *J Manag Care Spec Pharm.* 2015 Dec;21(12):1134-43.

Holländer-Mieritz C, Johansen J, Johansen C, Vogelius IR, Kristensen CA, Pappot H. Comparing the patients' subjective experiences of acute side effects during radiotherapy for head and neck cancer with four different patient-reported outcomes questionnaires. *Acta Oncol.* 2019 Jan 30:1-7. doi: 10.1080/0284186X.2018.1563713.

Honvo G, Leclercq V, Geerinck A, Thomas T, Veronese N, Charles A, Rabenda V, Beudart C, Cooper C, Reginster JY, Bruyère O. *Drugs Aging.* Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. 2019 Apr;36(Suppl 1):45-64. doi: 10.1007/s40266-019-00661-0.

Honvo G, Reginster JY, Rabenda V, Geerinck A, Mkinsi O, Charles A, Rizzoli R, Cooper C, Avouac B, Bruyère O. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis *Drugs Aging.* 2019 Apr;36(Suppl 1):65-99. doi: 10.1007/s40266-019-00662-z.

Honvo G, Reginster JY, Rannou F, Rygaert X, Geerinck A, Rabenda V, McAlindon T, Charles A, Fuggle N, Cooper C, Curtis E, Arden N, Avouac B, Bruyère O. Safety of Intra-articular Hyaluronic Acid Injections in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. *Drugs Aging.* 2019 Apr;36(Suppl 1):101-127. doi: 10.1007/s40266-019-00657-w.

Huang J, Jia Y, Sun S, Meng L. Adverse event profiles of dipeptidyl peptidase-4 inhibitors: data mining of the public version of the FDA adverse event reporting system. *BMC Pharmacol Toxicol.* 2020 Sep 16;21(1):68. doi: 10.1186/s40360-020-00447-w. PMID: 32938499; PMCID:

Inácio P, Airaksinen M, Cavaco A. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese. *Res Social Adm Pharm.* 2014 Dec 5. pii: S1551-7411(14)00397-0.

Jessurun N, van Puijenbroek E. Relationship Between Structural Alerts in NSAIDs and Idiosyncratic Hepatotoxicity: An Analysis of Spontaneous Report Data from the WHO Database. *Drug Saf.* 2015 Mar 19.

Ji HH, Tang XW, Dong Z, Song L, Jia YT. Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS. *Clin Drug Investig.* 2019 Jan 23. doi: 10.1007/s40261-018-0735-0.

Jia Y, Zhu C, Du J, Xiang Y, Chen Y, Wang W, Tao C. Investigating safety profiles of human papillomavirus vaccine across group differences using VAERS data and MedDRA. *PeerJ.* 2019 Aug



20; 7:e7490. doi: 10.7717/peerj.7490. eCollection 2019.

Kang S, Niak A, Gada N, Brinker A, Jones SC. Etonogestrel implant migration to the vasculature, chest wall, and distant body sites: cases from a pharmacovigilance database. *Contraception*. 2017 Sep 1.

Karapetiantz P, Bellet F, Audeh B, Lardon J, Leprovost D, Aboukhamis R, Morlane-Hondère F, Grouin C, Burgun A, Katsahian S, Jaulent MC, Beyens MN, Lillo-Le Louët A, Bousquet C. Descriptions of Adverse Drug Reactions Are Less Informative in Forums Than in the French Pharmacovigilance Database but Provide More Unexpected Reactions. *Front Pharmacol*. 2018 May 1; 9:439. 2018.

Karimi S, Kemps M, Metke-Jimenez A, Wang C.2 Cadec: A Corpus of Adverse Drug Event Annotations. *J Biomed Inform*. 2015 Mar 26. pii: S1532-0464(15)00053-2.

Lasky JA, Criner GJ, Lazarus HM, Kohlbrenner V, Bender S, Richeldi L. Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance Data [published online ahead of print, 2020 Aug 7]. *Adv Ther*. 2020;10.1007/s12325-020-01452-5. doi:10.1007/s12325-020-01452-5

Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orłowski RZ, Moreau P, Rosiñol L, Faber EA Jr, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. *Br J Haematol*. 2017 May 3.

Lavonas EJ, Banner W, Bradt P, Bucher-Bartelson B, Brown KR, Rajan P, Murrelle L, Dart RC, Green JL. Root Causes, Clinical Effects, and Outcomes of Unintentional Exposures to Buprenorphine by Young Children. *J Pediatr*. 2013 Nov;163(5):1377-83.

Ly T, Pamer C, Dang O, Brajovic S, Haider S, Botsis T, Milward D, Winter A, Lu S, Ball R. J. Evaluation of Natural Language Processing (NLP) Systems to Annotate Drug Product Labeling with MedDRA Terminology. *Biomed Inform*. 2018 May 31.

Mali G, Ahuja V, Dubey K. Glucagon-like peptide-1 analogues and thyroid cancer: An analysis of cases reported in the European pharmacovigilance database. *J Clin Pharm Ther*. 2020 Sep 14. doi: 10.1111/jcpt.13259. Epub ahead of print. PMID: 32926446.

Marcilly R, Douze L, Ferré S, Audeh B, Bobed C, Lillo-Le Louët A, Lamy JB, Bousquet C. How to interact with medical terminologies? Formative usability evaluations comparing three approaches for supporting the use of MedDRA by pharmacovigilance specialists. *BMC Med Inform Decis Mak.* 2020 Oct 9;20(1):261. doi: 10.1186/s12911-020-01280-1. PMID: 33036603; PMCID: PMC7547416.

Martin Arias LH, Martin Gonzalez A, Sanz Fadrique R, Salgueiro E, Sainz M. Cardiovascular and gastrointestinal safety of selective cyclooxygenase-2 inhibitors: a case/non-case study. *Int J Clin Pharm.* 2018 Jul 31. doi: 10.1007/s11096-018-0705-x.

Mendes D, Alves C, Loureiro M, Fonte A, Batel-Marques F. Drug-induced hypersensitivity: A 5-year retrospective study in a hospital electronic health records database. *J Clin Pharm Ther.* 2018 Aug 1. doi: 10.1111/jcpt.12752.

Mendes D, Oliveira AR, Alves C, Batel Marques F. Spontaneous reports of hypersensitivity adverse drug reactions in Portugal: a retrospective analysis. *Expert Opin Drug Saf.* 2020 Mar 25:1-7. doi: 10.1080/14740338.2020.1743262. [Epub ahead of print] PubMed PMID: 32167395.

Merchant L, Lutter R, Chang S. Identical or similar brand names used in different countries for medications with different active ingredients: a descriptive analysis [published online ahead of print, 2020 Apr 27]. *BMJ Qual Saf.* 2020;bmjqs-2019-010316. doi:10.1136/bmjqs-2019-010316

Min KC, Woo T, Assaid C, McCrea J, Gurner DM, Sisk CM, Adkinson F, Herring WJ. Incidence of hypersensitivity and anaphylaxis with sugammadex. *J Clin Anesth.* 2018 Apr 2; 47:67-73.

Minjon L, van den Ban E, de Jong E, Souverein PC, Egberts TCG, Heerdink ER. Reported Adverse Drug Reactions in Children and Adolescents Treated with Antipsychotics. *J Child Adolesc Psychopharmacol.* 2019 Jan 24. doi: 10.1089/cap.2018.0139.

Miravittles M, Price D, Rabe KF, Schmidt H, Metzdorf N, Celli B. Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis.* 2015 Mar 16;10:549-64. 2015.

Misu T, Kortepeter CM, Muñoz MA, Wu E, Dal Pan GJ. An Evaluation of "Drug Ineffective" Postmarketing Reports in Drug Safety Surveillance. *Drugs Real World Outcomes.* 2018 Feb 23.

Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D'Amico R, Dickersin K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, Mugelli A, Mühlbauer B, Püntmann I, Reeves B, Rogers C, Schmucker C, Subramanian ML, Virgili G. Systemic safety of bevacizumab

versus ranibizumab for neovascular age-related macular degeneration. *Cochrane Database Syst Rev*. 2014 Sep 15;9:CD011230.

Monaco L, Melis M, Biagi C, Donati M, Sapigni E, Vaccheri A, Motola D. Signal detection activity on EudraVigilance data: analysis of the procedure and findings from an Italian Regional Centre for Pharmacovigilance. *Expert Opin Drug Saf*. 2017 Jan 30;1-5.

Moore TJ, Glenmullen J, Mattison DR. Reports of Pathological Gambling, Hypersexuality, and Compulsive Shopping Associated With Dopamine Receptor Agonist Drugs. *JAMA Intern Med*. 2014 Oct 20.

Moro PL, Winiacki S, Lewis P, Shimabukuro TT, Cano M. Surveillance of adverse events after the first trivalent inactivated influenza vaccine produced in mammalian cell culture (Flucelvax®) reported to the Vaccine Adverse Event Reporting System (VAERS), United States, 2013-2015. *Vaccine*. 2015 Oct 27. pii: S0264-410X(15)01527-3.

Moro PL, Woo EJ, Paul W, Lewis P, Petersen BW, Cano M . Post-Marketing Surveillance of Human Rabies Diploid Cell Vaccine (Imovax) in the Vaccine Adverse Event Reporting System (VAERS) in the United States. *PLoS Negl Trop Dis*. 2016 Jul 13;10(7):e0004846.

Motola D, Donati M, Biagi C, Calamelli E, Cipriani F, Melis M, Monaco L, Vaccheri A, Ricci G. Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase. *Pharmacoepidemiol Drug Saf*. 2017 Jun 27.

Mukai J, Maruyama S, Otori K, Kubota R. [Antidepressant Medication Use and Development of Hyperglycemia and Diabetes Mellitus: A Japanese Adverse Drug Event Report Database Study]. *Yakugaku Zasshi*. 2020;140(4):591-598. doi: 10.1248/yakushi.19-00196. Japanese. PubMed PMID: 32238642.

Mukai M, Mould D, Maeda H, Narushima K, Greene D. Exposure-Response Analysis for Mogamulizumab in Adults With Cutaneous T-Cell Lymphoma. *J Clin Pharmacol*. 2020 Jan;60(1):50-57. doi: 10.1002/jcph.1548. Epub 2019 Dec 16. PMID: 31840837

Naganuma M, Tahara K, Hasegawa S, Fukuda A, Sasaoka S, Hatahira H, Motooka Y, Nakao S, Mukai R, Hirade K, Yoshimura T, Kato T, Takeuchi H, Nakamura M. Adverse event profiles of solvent-based and nanoparticle albumin-bound paclitaxel formulations using the Food and Drug Administration Adverse Event Reporting System. *SAGE Open Med*. 2019 Mar 11;7:2050312119836011. doi: 10.1177/2050312119836011.

Nakao S, Hasegawa S, Shimada K, et al. Evaluation of anti-infective-related *Clostridium difficile*-associated colitis using the Japanese Adverse Drug Event Report database. *Int J Med Sci.* 2020;17(7):921-930. Published 2020 Mar 26. doi:10.7150/ijms.43789

Narushima D, Kawasaki Y, Takamatsu S, Yamada H. Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression model. *PeerJ.* 2016 Mar 8.

Nasso C, Mecchio A, Rottura M, et al. A 7-Years Active Pharmacovigilance Study of Adverse Drug Reactions Causing Children Admission to a Pediatric Emergency Department in Sicily. *Front Pharmacol.* 2020;11:1090. Published 2020 Jul 17. doi:10.3389/fphar.2020.01090

Neeland IJ, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi SE, Wanner C, Zwiener I, Wojeck BS, Yaggi HK, Johansen OE; EMPA-REG OUTCOME Investigators. The Impact of Empagliflozin on Obstructive Sleep Apnea, Cardiovascular, and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. *Diabetes Care.* 2020 Oct 1;dc201096. doi: 10.2337/dc20-1096. Epub ahead of print. PMID: 33004464.

Nevin RL, Byrd AM. Neuropsychiatric Adverse Reactions to Mefloquine: a Systematic Comparison of Prescribing and Patient Safety Guidance in the US, UK, Ireland, Australia, New Zealand, and Canada. *Neurol Ther.* 2016 May 30.

Newbould V, Le Meur S, Goedecke T, Kurz X. Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance. *Drug Saf.* 2017 Jul 11.

Nishtala PS, Gill S, Chyou TY. Analysis of the US FDA adverse event reporting system to identify adverse cardiac events associated with hydroxychloroquine in older adults. *Pharmacoepidemiol Drug Saf.* 2020 Oct 19. doi: 10.1002/pds.5155. Epub ahead of print. PMID: 33078448.

Novitt-Moreno A, Ransom J, Dow G, Smith B, Read LT, Toovey S, Tafenoquine for malaria prophylaxis in adults: An integrated safety analysis. *Travel Med Infect Dis.* 2017 May 8.

Ogar CK, Abiola A, Yuah D, et al. A Retrospective Review of Serious Adverse Drug Reaction Reports in the Nigerian VigiFlow Database from September 2004 to December 2016. *Pharmaceut Med.* 2019;33(2):145–157. doi:10.1007/s40290-019-00267-2

Ohyama K, Inoue M. Association between Selective Beta-adrenergic Drugs and Blood Pressure Elevation: Data Mining of the Japanese Adverse Drug Event Report (JADER) Database. *Yakugaku*

Zasshi. 2016; 136(7):1065-71.

Orion K, Mack J, Kullak-Ublick GA, Weiler S. Kounis syndrome: A retrospective analysis of individual case safety reports from the international WHO database in pharmacovigilance. *Int J Clin Pharmacol Ther.* 2019 Mar 22. doi: 10.5414/CP203344.

Patel R, Belousov M, Jani M, Dasgupta N, Winokur C, Nenadic G, Dixon WG. Frequent discussion of insomnia and weight gain with glucocorticoid therapy: An analysis of Twitter posts. *NPJ Digit Med.* 2018 Feb 12;1. doi: 10.1038/s41746-017-0007-z.

Perino J, Mottal N, Bohbot Y, Servant V, Berroneau A, Poustis P, Fenaux P, Laribi K, Charbonnier A, Bilion E, Calmettes C, Bégau B, Pigneux A, Milpied N, Miremont-Salamé G, Théophile H, Dimicoli-Salazar S. Cardiac failure in patients treated with azacitidine, a pyrimidine analogue: case reports and disproportionality analyses in Vigibase®. *Br J Clin Pharmacol.* 2020 Jan 7. doi: 10.1111/bcp.14211. [Epub ahead of print]

PMID: 31912911

Pierce CE, Bouri K, Pamer C, Proestel S, Rodriguez HW, Van Le H, Freifeld CC, Brownstein JS, Walderhaug M, Edwards IR, Dasgupta N. Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts. *Drug Saf.* 2017 Jan 2.

Pinheiro L, Blake K, Januskiene J, Yue QY, Arlett P. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance. *Pharmacoepidemiol Drug Saf.* 2016 Mar 22.

Pollock RF, Biggar P. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. *Expert Rev Hematol.* 2020;13(2):187–195. doi:10.1080/17474086.2020.1709437

Powell GE, Seifert HA, Reblin T, Burstein PJ, Blowers J, Menius JA, Painter JL, Thomas M, Pierce CE, Rodriguez HW, Brownstein JS, Freifeld CC, Bell HG, Dasgupta N. Social Media Listening for Routine Post-Marketing Safety Surveillance. *Drug Saf.* 2016 Jan 21.

Pratley RE, Husain M, Lingvay I, Pieber TR, Mark T, Saevereid HA, Møller DV, Zinman B; DEVOTE Study Group. Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. *Cardiovasc Diabetol.* 2019 Nov 15;18(1):156. doi: 10.1186/s12933-019-0960-8.

Rademacher WMH, Aziz Y, Hielema A, Cheung KC, de Lange J, Vissink A, Rozema FR. Oral adverse effects of drugs: taste disorders. *Oral Dis.* 2019 Sep 18. doi: 10.1111/odi.13199.

Raschi E, Poluzzi E1, Koci A, Antonazzo IC, Marchesini G, De Ponti F. Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System. *Nutr Metab Cardiovasc Dis.* 2016 Feb 19. pii: S0939-4753(15)30192-7.

Reiber R, Wolf H, Schnitker J, Wüstenberg E. Tolerability of an Immunologically Enhanced Subcutaneous Immunotherapy Preparation in Patients Treated with Concomitant Allergy Immunotherapy: A Non-Interventional Observational Study. *Drugs Real World Outcomes.* 2017 Jan 9.

Rochoy M, Auffret M, Béné J, Gautier S; Réseau français des centres régionaux de pharmacovigilance. Antiemetics and cardiac effects potentially linked to prolongation of the QT interval: Case/non-case analysis in the national pharmacovigilance database *Rev Epidemiol Sante Publique.* 2016 Dec 14. pii: S0398-7620(16)30811-2.

Rodríguez Del Río P, Vidal C, Just J, Tabar AI, Sanchez-Machin I, Eberle P, Borja J, Bubel P, Pfaar O, Demoly P, Calderón MA. The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSD): a paediatric assessment. *Pediatr Allergy Immunol.* 2016 Sep 17.

Sakai T, Ohtsu F, Sekiya Y, Mori C, Sakata H, Goto N. Methodology for Estimating the Risk of Adverse Drug Reactions in Pregnant Women: Analysis of the Japanese Adverse Drug Event Report Database. *Yakugaku Zasshi.* 2016;136(3):499-505.

Sandhu A, Kao D, Mehler PS, Haigney MC, Krantz MJ. Cardiovascular disorders associated with naloxone monotherapy and in fixed-dose combination with opioids: Data from international safety surveillance. *Int J Cardiol.* 2016 Jun 1;212:360-3.

Sarntivijai S, Xiang Z, Shedden KA, Markel H, Omenn GS, Athey BD, He Y. Ontology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines. *PLoS One.* 2012;7(11). Epub 2012 Nov 28.

Sasaoka S, Hatahira H, Hasegawa S1, Motooka Y, Fukuda A, Naganuma M, Umetsu R1, Nakao S, Shimauchi A, Ueda N, Hirade K, Iguchi K, Nakamura M. Adverse Event Trends Associated with Over-the-counter Combination Cold Remedy: Data Mining of the Japanese Adverse Drug Event Report Database. *Yakugaku Zasshi.* 2018; 138(1):123 -134.

Schmitz B, Dimova S, Zhang Y, Chellun D, De Backer M, Gasalla T. Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial. *Epilepsy Res.* 2019 Oct 16;159:106220. doi: 10.1016/j.epilepsyres.2019.106220.

Schmitz SM MD, MPH1, Lopez HL MD, MS1,2, Mackay D ND3, Nguyen H BS3, Miller PE BS1. Serious Adverse Events Reported with Dietary Supplement Use in the United States: A 2.5 Year Experience. *J Diet Suppl.* 2018 Dec 4:1-22. doi: 10.1080/19390211.2018.1513109.

Sessa M, Mascolo A, Callréus T, Capuano A, Rossi F, Andersen M. Direct-acting oral anticoagulants (DOACs) in pregnancy: new insight from VigiBase®. *Sci Rep.* 2019 May 10;9(1):7236. doi: 10.1038/s41598-019-43715-4.

Sloan VS, Jones A, Maduka C, Bentz JWG. A Benefit Risk Review of Pediatric Use of Hydrocodone/Chlorpheniramine, a Prescription Opioid Antitussive Agent for the Treatment of Cough. *Drugs Real World Outcomes.* 2019 Jun;6(2):47-57. doi: 10.1007/s40801-019-0152-6.

Shimada K, Hasegawa S, Nakao S, Mukai R, Matsumoto K, Tanaka M, Uranishi H1., Masuta M, Nishida S, Shimizu S, Hayashi Y, Suzuki A, Nakamura M. Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases. *Cancer Chemother Pharmacol.* 2019 Sep 9. doi: 10.1007/s00280-019-03949-5.

Stainsby CM, Perger TM, Vannappagari V, Mounzer KC, Hsu RK, Henegar CE, Oyee J, Urbaityte R, Lane CE1, Carter LM, Pakes GE, Shaefer MS. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B\*5701 Screening as a Risk Mitigation Measure. *Pharmacotherapy.* 2018 Nov 10. doi: 10.1002/phar.2196.

Tao C, He Y, Arabandi S. Vaccine and Drug Ontology Studies (VDOS 2014). *J Biomed Semantics.* 2016 Feb 25;7:6.

Tao C, Du J, Cai Y, Chen Y. Trivalent Influenza Vaccine Adverse Event Analysis Based On MedDRA System Organ Classes Using VAERS Data. *Stud Health Technol Inform.* 2015;216:1076.

Tao C, He Y, Arabandi S. A 2013 workshop: vaccine and drug ontology studies (VDOS 2013). *J Biomed Semantics.* 2014 Mar 20; 5(1):16.

Taylor E, Vu D, Legare C, Keene D. Intravenous immune globulin-related hemolysis: comparing two different methods for case assessment. *Transfusion*. 2015 Jul;55 Suppl 2:S23-7.

Teng C, Reveles KR, Obodozie-Ofoegbu OO, Frei CR. Clostridium difficile Infection Risk with Important Antibiotic Classes: An Analysis of the FDA Adverse Event Reporting System. *Int J Med Sci*. 2019 May 7;16(5):630-635. doi: 10.7150/ijms.30739. eCollection 2019.

Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System. *Int J Med Sci*. 2019 Jun 10;16(7):1018-1022. doi: 10.7150/ijms.34141.

Tourillon C, Mahe J, Baron A, Lambert A, Yélehé-Okouma M, Veyrac G, Jolliet P. Immediate-Type Hypersensitivity Cross-Reactions to Proton Pump Inhibitors: A Descriptive Study of Data from the French National Pharmacovigilance Database. *Int Arch Allergy Immunol*. 2018 Nov 28:1-8. doi: 10.1159/000493581.

Trippe ZA, Brendani B, Meier C, Lewis D. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports. *Drug Saf*. 2017 Jan 28.

Uemura N, Kinoshita Y, Haruma K, Yao T, Kushima R, Kanoo T. Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis. *Clin Exp Gastroenterol*. 2018 Jan 24; 11:51-56.

Vacher R, Lagarce L, Ghamrawi S, Laugier-Castellan D, Vial T, Bagheri H, Babin M, Briet M. Drug interactions related to self-medication: a French pharmacovigilance database study. *Fundam Clin Pharmacol*. 2020 Feb 16. doi: 10.1111/fcp.12546. [Epub ahead of print] PubMed PMID: 32064672.

van Hunsel F, van de Koppel S, van Puijenbroek E, Kant A. Vitamin B6 in Health Supplements and Neuropathy: Case Series Assessment of Spontaneously Reported Cases. *Drug Saf*. 2018 May 8.

van Hunsel F, van de Koppel S, Skalli S, Kuemmerle A, Teng L, Wang JB, Barnes J. Analysis of Hepatobiliary Disorder Reports Associated With the Use of Herbal Medicines in the Global Suspected ADR Database Vigibase. *Front Pharmacol*. 2019 Nov 6;10:1326. doi: 10.3389/fphar.2019.01326. eCollection 2019.

Vandael E, Vandenberg B, Vandenberghe J, Willems R, Foulon V. Cases of drug-induced Torsade de Pointes: a review of Belgian cases in the EudraVigilance database. *Acta Clin Belg*. 2017 Mar 24: 1-6.



Vergani HM, Calvini G, Mangini G, Mattioli F, Parodi A, Burlando M, Bodini G, Martelli A. Active pharmacovigilance program in patients affected by psoriasis and inflammatory bowel diseases. *Int J Clin Pharmacol Ther.* 2020 Feb 12. doi:10.5414/CP203628. [Epub ahead of print] PubMed PMID: 32053103.

Vidal C, Rodríguez Del Río P, Gude F, Casale T, Cox L, Just J, Pfaar O, Demoly P, Calderón MA. Comparison of International Systemic Adverse Reactions due to Allergen Immunotherapy. *J Allergy Clin Immunol Pract.* 2018 Dec 14. pii: S2213-2198(18)30826-2. doi: 10.1016/j.jaip.2018.12.006.

Viola E, Opri S, Moretti U, Leone R, Casini ML, Ruggieri S, Minore C, Conforti A.  $\alpha$ 1-Adrenergic receptor antagonists and gynecomastia. A case series from the Italian spontaneous reporting system and VigiBase™. *Eur J Clin Pharmacol.* 2014 Jun 3.

Vollmer O, Felten R, Mertz P, Lebrun-Vignes B, Salem JE, Arnaud L. Characterization of autoimmune hepatitis associated with the use of anti-TNF $\alpha$  agents: An analysis of 389 cases in VigiBase [published online ahead of print, 2020 Jan 7]. *Autoimmun Rev.* 2020;102460. doi:10.1016/j.autrev.2020.102460

Wang L, Li M, Cao Y, Han Z, Wang X, Atkinson EJ, Liu H, Amin. Proton Pump Inhibitors and the Risk for Fracture at Specific Sites: Data Mining of the FDA Adverse Event Reporting System. *Sci Rep.* 2017 Jul 17.

Wise RA, Anderson JA, Amarenco P, et al. Adjudication of cardiovascular events in patients with chronic obstructive pulmonary disease: SUMMIT trial [published online ahead of print, 2020 May 22]. *Clin Trials.* 2020;1740774520920897. doi:10.1177/1740774520920897

Xie J, He Y. Ontology-Based Vaccine Adverse Event Representation and Analysis. *Adv Exp Med Biol.* 2017;1028:89-103.

Xie J, Zhao L, Zhou S, He Y. Statistical and Ontological Analysis of Adverse Events Associated with Monovalent and Combination Vaccines against Hepatitis A and B Diseases. *Sci Rep.* 2016 Oct 3;6:34318.

Ye JH, Ho YF, On AW, Chen WW, Huang YM, Huang WI, Tang YW. Trends in reporting drug-associated liver injuries in Taiwan: a focus on amiodarone. *Int J Clin Pharm.* 2018 Jul 26. doi: 10.1007/s11096-018-0698-5.

Yu Y, Ruddy KJ, Hong N, Tsuji S, Wen A, Shah ND, Jiang G. ADEpedia-on-OHDSI: A Next Generation

Pharmacovigilance Signal Detection Platform Using the OHDSI Common Data Model. *J Biomed Inform.* 2019 Feb 7:103119. doi: 10.1016/j.jbi.2019.103119.

Yue Z, Jiang P, Sun H, Wu J. Association between an excess risk of acute kidney injury and concomitant use of ibuprofen and acetaminophen in children, retrospective analysis of a spontaneous reporting system. *Eur J Clin Pharmacol.* 2014 Jan 21.

Zhang X, Zhong Z, Li Y, Li W. Long-term renal outcomes associated with sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and meta-analysis. *Diabetes Metab Res Rev.* 2020 Mar 5:e3303. doi: 10.1002/dmrr.3303. [Epub ahead of print] PubMed PMID: 32134558.

Zhu Z, Gao P, Hu Y, Wang J, Wang H, Yang J, Huang L, Ji C, Ni Y, Fang L. PEGylated versus non-PEGylated drugs: A cross-sectional analysis of adverse events in the FDA Adverse Event Reporting System (FAERS) Database. *Int J Clin Pharmacol Ther.* 2020 Apr 23. doi: 10.5414/CP203735. [Epub ahead of print] PubMed PMID: 32324132.

Ziemssen Fs, Hammer T, Grueb M, Mueller B, Berk H, Gamulescu MA, Voegeler J, Wachtlin J, Ocean Study Group. Reporting of Safety Events during Anti-VEGF Treatment: Pharmacovigilance in a Noninterventional Trial. *J Ophthalmol.* 2020 Oct 6;2020:8652370. doi: 10.1155/2020/8652370. PMID: 33083052; PMCID: PMC7558801.

Peng L, Xiao K, Ottaviani S, Stebbing J, Wang YJ. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. *Expert Opin Drug Saf.* 2020 Nov;19(11):1505-1511. doi: 10.1080/14740338.2020.1799975. Epub 2020 Jul 31.